The Moores UCSD Cancer Center has started enrolling eligible patients in a trial of a new vaccine for lung cancer.

Called Lucanix™, the vaccine is designed to help a patient’s immune system fight the tumor. It was developed by a local biotechnology company.

The chief investigator in the study is Lyudmila Bazhenova, M.D., Assistant Clinical Professor of Medicine in the Division of Hematology-Oncology. Dr. Bazhenova directs the Lung Cancer Unit at the Cancer Center.

Read the full story
from UC San Diego
Health Sciences Communications

Learn more about
the Lucanix™ trial

More Information

%d bloggers like this: